Gene therapy holds the promise of treating the unmet needs of patients who suffer from a rare genetic disease. An estimated 4,000 medical conditions are a result of gene disorders with no previous targeted treatments. Gene therapy offers new options away from the conventional symptomatic approach to disease treatment as well as provides hope for real cures.
At Catalent, we understand the unique and complex nature of bringing a gene therapy to market and are dedicated to achieving the best approach for your product from start to finish. As unique as the therapies themselves, every path from the bench to the clinic is tailored to ensure that your results are timely and efficient. We are here to optimize your viral development and streamline your manufacturing process for optimal and reliable titers to achieve a stable and effective product dose.
The Paragon Gene Therapy team at Catalent combines decades of bioproduction experience and world-class clinical and commercial facilities with 3 years of intense AAV gene therapy development and manufacturing success to create a complete program for your product. From DNA to final fill and finish, our team is with you every step of the way. We know you may have just one chance to bring the next transformative medicine to market and at Catalent, we are ready to commit our time, attention and ingenuity to meet your therapeutic milestones.